Seqirus Vaccines Limited Sustainability Profile
Seqirus Vaccines Limited, headquartered in Great Britain, is a leading player in the global vaccine industry, specialising in the development and production of innovative vaccines. Founded in 2015, Seqirus emerged from the merger of bioCSL and Novartis Vaccines, quickly establishing itself as a key provider of seasonal influenza vaccines and other critical immunisation solutions. With a strong operational presence across Europe, North America, and Asia-Pacific, Seqirus is dedicated to addressing public health needs through its advanced vaccine technologies. The company’s core products include a range of flu vaccines, which are distinguished by their high efficacy and safety profiles. Notably, Seqirus has achieved significant milestones, including the development of the first adjuvanted flu vaccine for older adults, reinforcing its commitment to innovation and excellence in vaccine delivery.
DitchCarbon Score
How does Seqirus Vaccines Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Seqirus Vaccines Limited's score of 46 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Seqirus Vaccines Limited's reported carbon emissions
Seqirus Vaccines Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of CSL Limited, which may influence its climate commitments and reporting practices. While Seqirus has not outlined its own reduction targets or initiatives, it is important to note that it inherits climate commitments from its parent company, CSL Limited. This includes potential targets set under the Science Based Targets initiative (SBTi) and disclosures made to the Carbon Disclosure Project (CDP), both of which are cascaded from CSL Limited. However, specific details regarding these targets or achievements have not been provided. As a part of the broader pharmaceutical and vaccine industry, Seqirus is expected to align with industry standards for sustainability and climate action, although specific commitments or performance metrics are not currently available.
How Carbon Intensive is Seqirus Vaccines Limited's Industry?
How Carbon Intensive is Seqirus Vaccines Limited's Location?
Seqirus Vaccines Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Seqirus Vaccines Limited has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.